Naratriptan Orifarm

Naratriptan, the active ingredient in Naratriptan Orifarm, is a Triptan presented as an oral tablet for oral use. It is employed for the acute treatment of migraine attacks in adults, helping to relieve headache and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Naratriptan Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. This includes both private and public sector procurement.

Naratriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute migraine treatment pathway. - Migraine attack: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: helps terminate the headache phase after aura subsides. - Migraine‑related nausea: reduces nausea and vomiting associated with an attack. - Migraine photophobia: lessens sensitivity to light during an attack. - Migraine phonophobia: diminishes sound sensitivity accompanying the headache.

Common and serious adverse reactions have been reported with naratriptan use. Common Side Effects: - Tingling or numbness in fingers or toes - Warmth or flushing sensation - Dizziness or light‑headedness - Dry mouth - Nausea - Fatigue Serious or Rare Side Effects: - Chest pain or tightness suggestive of coronary spasm - Severe allergic reaction including rash, swelling, or anaphylaxis - Serotonin syndrome manifested by agitation, fever, or muscle rigidity - Severe hypertension - Vision disturbances

When prescribing naratriptan, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular disease: avoid in patients with coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. - Age considerations: use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Hepatic impairment: dose adjustment may be required in moderate to severe liver dysfunction. - Pregnancy and lactation: safety has not been established; prescribe only if potential benefit justifies the risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Ergot alkaloids: concurrent use can cause excessive vasoconstriction and increase risk of serious cardiovascular events. - Monoamine oxidase inhibitors (MAOIs): combined therapy may precipitate severe hypertension or serotonin syndrome. - Other triptans: using more than one triptan within 24 hours can raise the risk of vasospastic complications. Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may increase serotonin levels, requiring observation for serotonin syndrome. - Antihypertensive agents: naratriptan’s vasoconstrictive action may diminish the blood‑pressure‑lowering effect. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise naratriptan plasma concentrations, potentially intensifying adverse effects.